Sign Up to like & get
recommendations!
0
Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx212
Abstract: Background Recent clinical results support the use of new immune checkpoint blockers (ICB), such as anti-PD-1 (e.g. nivolumab and pembrolizumab) and anti-PD-L1 antibodies. Radiological evaluation of ICB efficacy during therapy is challenging due to tumor…
read more here.
Keywords:
study;
ctdna levels;
circulating tumor;
tumor dna ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.995
Abstract: Introduction In precision oncology it is a great interest to develop novel disease and therapy monitoring technologies that are non-invasive and highly sensitive. Specifically, our project aims to establish blood-based assays that allow ‘real-time’ monitoring…
read more here.
Keywords:
ctdna;
disease;
ctdna levels;
melanoma patients ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-1324
Abstract: Purpose: We evaluated the predictive and prognostic value of circulating tumor DNA (ctDNA) in patients with Ewing sarcoma (EWS) treated in the EWING2008 trial. Experimental Design: Plasma samples from 102 patients with EWS enrolled in…
read more here.
Keywords:
ctdna levels;
response;
ctdna;
ewing sarcoma ... See more keywords
Sign Up to like & get
recommendations!
3
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb289
Abstract: Background: The role of circulating tumor DNA (ctDNA) in monitoring response to immunotherapy in NSCLC is unconfirmed. This is a retrospective analysis of association between longitudinal ctDNA levels and clinical outcomes in 1L TIS (anti-PD-1)…
read more here.
Keywords:
ctdna;
pfs;
rationale 304;
ctdna levels ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancers"
DOI: 10.3390/cancers14102479
Abstract: Simple Summary An early assessment of response to treatment is crucial to informing appropriate therapeutic management. Using a plasma-only strategy, we measured changes in circulating tumor DNA (ctDNA) levels after one or two cycles of…
read more here.
Keywords:
lung cancer;
early assessment;
treatment;
ctdna levels ... See more keywords